Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 17331Y109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. 13D/A | 71.0% |
6/4/2026
Event 5/15/2026
|
|
|
Armistice Capital, LLC
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
|
| Armistice Capital, LLC | 10.0% | ||
| Steven Boyd | 10.0% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 121 k | $121 k |
| 2026 Q2 | 19 | 14.1 M | $9.20 M |
| 2026 Q1 | 14 | 14.2 M | $8.83 M |
| 2025 Q4 | 18 | 6.86 M | $6.86 M |
| 2025 Q3 | 16 | 8.36 M | $17.0 M |
| 2025 Q2 | 8 | 227 k | $990 k |
| 2025 Q1 | 7 | 105 k | $97.7 k |
| 2024 Q4 | 12 | 201 k | $230 k |
| 2024 Q3 | 8 | 41.2 k | $57.0 k |